← All Abivax SA filings

Abivax SA 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
ABVX
Abivax SA
20-F: Abivax Reports Strong Phase 3 UC Data, Secures Major Funding
Abivax announced positive Phase 3 induction trial results for obefazimod in ulcerative colitis and significantly bolstered its financial position with a $747.5 million public offering, extending its cash runway into Q4 2027.
NASDAQ
ABVX
Abivax SA
20-F: Abivax SA Files 20-F Report, Outlines Financials and Strategic Outlook
Abivax SA releases its 20-F filing, detailing financial results, strategic initiatives, and risk factors for the fiscal year ended December 31, 2024.
NASDAQ
ABVX
Abivax SA
20-F: Abivax Details Share Warrant and Free Share Plans in Latest Filing
Abivax outlines the terms and conditions of its outstanding share warrant and free share plans as of January 1, 2024.